Ikarian Capital, LLC Blueprint Medicines Corp Call Options Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 13, 2022	BUY	$54.1 - $110.08 $3.46 Million - $7.05 Million	64,000 New	64,000 $4.09 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $8.53 Million - $11.9 Million	-128,400 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $4.48 Million - $6.21 Million	78,400 Added 156.8%	128,400 $10 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $2.41 Million - $4.11 Million	50,000 New	50,000 $2.92 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.